Skip to main content

Table 2 Patients treated with second/further-line HDIFX chemotherapy: clinical characteristics and response evaluation

From: Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma

Patients ID Gender Age at time of diagnosis (years) Myxofibrosarcoma grade Site of primary tumour Site of relapse at time of CT Response evaluation criteria in solid tumours (RECIST) evaluation
1 F 62 3 Groin Abdomen PD
2 F 43 3 Right arm Lung PD
3 M 71 2 Left thigh Lung PR
4 M 54 2 Left thigh Lung PR
5 F 72 2 Right arm Local relapse SD
6 M 46 3 Thoracic wall Local relapse RC
7 F 60 3 Right arm Lung PD
8 M 74 2 Left thigh Lung PD
9 M 57 1 Groin Local relapse PR
10 F 33 3 Abdomen Lung and abdomen PR
11 M 34 3 Right thigh Lung PD
12 M 71 3 Right arm Lung PR
13 M 70 1 sex cord Local relapse PR
14 F 48 1 Left thigh Local relapse SD
15 M 51 2 Left thigh Lung PD
16 F 27 2 Abdomen Abdomen SD
17 M 67 1 Left thigh Local relapse PD
18 M 56 2 Thoracic wall Lung PD
19 F 44 3 Right thigh Local relapse PD
20 M 51 3 Left leg Lung PR
21 M 64 2 Abdomen Lung PD
22 F 75 2 Right arm Local relapse PR
23 M 50 1 Right thigh Local relapse PR
24 M 65 2 Left thigh Lung PD
25 M 58 3 Left arm Lung PD
26 F 33 3 Left thigh Lung and abdomen PD
27 F 50 1 Thoracic wall Lung and abdomen SD
28 M 51 3 Left thigh Lung PD
  1. M male, F female, PR partial response, SD stable disease, PD progressive disease